AIIMS Delhi develops mobile apps to deal with mental illness

New Delhi: The All India Institute of Medical Sciences (AIIMS) in Delhi has developed two mobile apps for patients suffering from chronic mental illness and their caretakers.

As the whole world is reeling under the Covid-19 pandemic, cases of anxiety and depression have gone up.

AIIMS has developed two mobile apps to deal with severe mental illness for patients suffering from chronic mental illness and for those who got the first episode of such symptoms. The two apps – ‘Shaksham’ and ‘Disha’ – are for both who undergoes first such episode of symptoms and for those having severe mental illness.

Mamta Sood, senior psychiatrist at AIIMS, told IANS, “We have developed two mobile apps — Shaksham and Disha — to deal with mental illness.”

She added that the Shaksham app is for those suffering from chronic mental illness, while the Disha app will benefit persons who undergo first such episode of symptoms.

Both the apps have been developed in collaboration with the computer science departments of Indraprastha Institute of Technology, Delhi, and the University of Warwick, UK. The project was funded by the National Institute of Health Research, UK.

“The apps will be available for free public use from January next year. We are more concerned about the patient data to be used in the apps and once the data restoration is secured, we will launch it by January next year,” Sood said.

“The apps will also send reminder to the care givers for medicines and other requirements of the patients,” she added.

Asked about the mental problems faced by people during the ongoing pandemic, Sood said that an AIIMS research conducted on healthcare workers has revealed that 50 per cent of the healthcare workforce are facing symptoms like anxiety, depression and stress.

However, she added that having such symptoms and having the disease are different, as symptoms do not affect the patients, while disease affects all.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’